Boehringer Ingelheim yesterday announced the expansion of its Animal Health business in China. One of the major moves is the opening of the Asian Veterinary Research & Development (R&D) Center in Zhangjiang, Shanghai.
ARTES Biotechnology has announced a collaboration with global pharmaceutical company, Boehringer Ingelheim Animal Health. ARTES Biotechnology specialises in recombinant protein production, process and vaccine development from microbial expression systems. ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
US – Governor Terry E. Branstad travelled to Sioux Center last week to attend the grand opening for one of three Boehringer Ingelheim Vetmedica, Inc. (BIVI) specialised vaccine research facilities.
BARCELONA, SPAIN - An important anniversary in the history of porcine circovirus type 2 (PCV2) has been marked at a special international pig veterinary satellite symposium held in Barcelona, Spain in June 2011 as part of the 6th International Symposium on Emerging and Re-emerging Pig Diseases.
Ingelheim, Germany, 13 December 2016 – Having reached the milestone of 1 billion doses sold since launch, yet another vaccine of Boehringer Ingelheim Animal Health crosses a significant threshold making it one of the leading vaccines for the control of Mycoplasma hyopneumoniae globally(1).
US - In the latest 'At the Meeting' (ATM) audio program on swine health from the Morrison Group, leading swine veterinarians take on the historic and novel work regarding porcine circovirus (PCV2), including prevention, new diagnostic methods and vertical transmission’s impact on pig production and sow herds.
Peter Davies
Get the latest news on Swine Health Subscribe to our newsletter